Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 4,291 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gastro-Intestinal Cancer Clear all

Conditions: Bowel Dysfunction, Constipation
Interventions: alvimopan, Placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 137
States / cities: Birmingham, Alabama • Calera, Alabama • Muscle Shoals, Alabama + 114 more

Conditions: NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric Cancer (GC), Endometrial Cancer
Interventions: TS-104; Drug
Lead sponsor: TwoStep Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Maumee, Ohio • Portland, Oregon • Fairfax, Virginia

Conditions: Colorectal Cancer, Lynch Syndrome
Interventions: Omega-3 fatty acid ethyl esters (2 gram); Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Melanoma, Solid Tumor, CRAF Gene Amplification, RAF1 Gene Amplification, BRAF Gene Fusion, BRAF Fusion, CRAF Gene Fusion, CRAF Fusion, RAF1 Gene Fusion, RAF1 Fusion, Thyroid Cancer, Papillary, Spitzoid Melanoma, Pilocytic Astrocytoma, Pilocytic Astrocytoma, Adult, Non Small Cell Lung Cancer, Non-Small Cell Adenocarcinoma, Colorectal Cancer, Pancreatic Acinar Carcinoma, Spitzoid Malignant Melanoma, Bladder Cancer, Bladder Urothelial Carcinoma, MAP Kinase Family Gene Mutation, RAF Mutation
Interventions: Tovorafenib; Drug
Lead sponsor: Day One Biopharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more

Conditions: Barrett Esophagus, Esophageal Neoplasms, Deglutition Disorders, GERD, Neoplasm
Interventions: CSA System (CryoSpray AblationTM System), CryoSpray Ablation; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Colon Cancer, Lung Cancer, Skin Cancer, Rectum Cancer
Interventions: Automated Telephone Symptom Management (ATMS) and Telephone Interpersonal Counseling (TIP-C), Active control comparator; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Phoenix, Arizona • Tucson, Arizona • Ann Arbor, Michigan

Conditions: Colorectal Cancer
Interventions: Optical colonoscopy, CT-Colonography; Procedure · Radiation
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 5
States / cities: Chicago, Illinois • Rochester, Minnesota • New York, New York + 2 more

Conditions: Colorectal Cancer
Interventions: fluorouracil, leucovorin calcium, oxaliplatin, conventional surgery, radiation therapy, laboratory biomarker analysis, DNA analysis, polymerase chain reaction, immunohistochemistry staining method; Drug · Procedure · Radiation + 2 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2026
U.S. locations: 14
States / cities: Concord, California • Duarte, California • Orange, California + 10 more

Conditions: Ovarian Neoplasms, Colorectal Neoplasms, Melanoma, Small Cell Lung Cancer, Liposarcoma
Interventions: Ionizing radiation (IR) therapy, Ionizing radiation (IR); Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer
Interventions: Aminolevulinic Acid, Biospecimen Collection, Computed Tomography, Fluorescence-Guided Surgery, Magnetic Resonance Imaging, Photodynamic Therapy, Surgical Procedure; Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Interventions: Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar, Fluoropyrimidine (FP); Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 30
States / cities: Anchorage, Alaska • Gilbert, Arizona • Cerritos, California + 23 more

Conditions: Anal Cancer, HPV-Related Carcinoma, Squamous Cell Carcinoma of the Anus
Interventions: HPV ctDNA Response based radiation, Chemotherapy, Retifanlimab; Radiation · Drug
Lead sponsor: Jennifer Dorth; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Colorectal Cancer
Interventions: leucovorin calcium, tegafur-uracil; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 75 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 49
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 35 more

Conditions: Colorectal Cancer, Colorectal Neoplasms
Interventions: Epi proColon; Device
Lead sponsor: Epigenomics, Inc; Industry
Eligibility: 50 Years to 74 Years
Enrollment: 4,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 6
States / cities: San Diego, California • Royal Oak, Michigan • New Brunswick, New Jersey + 3 more

Conditions: Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Renal Cancer, Head and Neck Cancer, Other Solid Cancers
Interventions: Autogene cevumeran, Atezolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 15
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 10 more

Conditions: Colorectal Cancer, Regorafenib, High Risk Patients
Interventions: Regorafenib (CT), Lorigerlimab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Ovarian Cancer, Prostate Cancer, Colon Cancer, Renal Cancer
Interventions: Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Boston, Massachusetts • Houston, Texas

Conditions: Gastric Cancer
Interventions: cisplatin, floxuridine, fluorouracil, leucovorin calcium, conventional surgery; Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2001
U.S. locations: 1
States / cities: New York, New York

Conditions: Surgery, Stomach Cancer, Pancreas Cancer, Bile Duct Cancer, Liver Cancer, Peritoneal Cancer
Interventions: Music-assisted relaxation and imagery (MARI); Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 50 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Breast Cancer, Gastrointestinal Cancer
Interventions: Capecitabine; Drug
Lead sponsor: Qamar Khan; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 15
States / cities: Fairway, Kansas • Garden City, Kansas • Great Bend, Kansas + 10 more

Conditions: Appendix Cancer, Pseudomyxoma Peritonei
Interventions: Not listed
Lead sponsor: Appendix Cancer Pseudomyxoma Peritonei Research Foundation; Other
Eligibility: Not listed
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Springfield, Pennsylvania

Conditions: Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma
Interventions: Biospecimen Collection, Cannabidiol, Dronabinol, Placebo Administration, Survey Administration; Procedure · Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Interventions: AZD0022, Cetuximab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Duarte, California • New York, New York • Fairfax, Virginia

Conditions: Gastric Cancer
Interventions: Observational study (no intervention); Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 329 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Duarte, California

Search by objective public record fields.

Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Study of Cryotherapy Treatment of Barrett's Esophagus and Early Esophageal Cancer

Adaptive Symptom Self-Management Immunotherapy Study

Comparative Effectiveness of CTC & OC

Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation

Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer

A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer

Fluorouracil-Uracil and Leucovorin in Treating Elderly Patients With Metastatic Colorectal Cancer

Longitudinal Performance of Epi proColon

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing

Combination Chemotherapy Before and After Surgery in Treating Patients With Stomach Cancer

TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)

Capecitabine in Metastatic Breast and GI Cancers

The Appendix Cancer PMP Research Foundation Natural History Study/Patient Registry

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation

Alternative Splicing Based Prediction of Chemotherapy Response in Gastric Cancer